Business
First UK commercial sales of the CYP2C19-ID Kit
First UK commercial sales of the CYP2C19-ID Kit.
About this update from Genedrive Plc
[{"type":"text","content":"\n\ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nFirst UK commercial sales of the Genedrive® CYP2C19-ID Kit\n \ngenedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that following the UK's National Institute for Health and Care Excellence (\"NICE\") final published guidance that CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic Stroke (\"IS\") or Transient Ischaemic Attack (\"TIA\"), and that the Genedrive® CYP2C19-ID test should be used as the test of choice for point of care strategies1, an initial order for the CYP2C19-ID Kit and instruments has been received (c.£0.1M) to support an implementation assessment at Greater Manchester's Comprehensive Stroke Centre (\"CSC\").\n \nHyperacute Stroke units (\"HASU\") are part of the UK's Integrated Stroke Delivery Network, where care typically covers the first 72 hours after admission, with the aim that every patient with acute stroke should gain rapid access to a stroke unit in under four hours and receive an early multidisciplinary assessment2. Greater Manchester CSC is the largest and busiest HASU in England with more than 2,000 stroke patient admissions per annum and is situated within the Manchester Centre for Clinical Neurosciences (\"MCCN\") at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust. The implementation assessment's aim is to establish the benefit for patients across Greater Manchester.\n \nUK NICE guidance recommends laboratory CYP2C19 genotyping, and where not available or possible to implement point of care strategies, using the Genedrive® CYP2C19-ID test as the platform of choice. Whilst positioned primarily for enabling near-patient point of care testing, the Genedrive® System is also suitable for traditional laboratory testing paradigms as a more affordable alternative to more expensive laboratory platforms where sample throughput requirements do not necessitate high-scale batch processing.\n \nFactoring in potential improvements in patient outcomes in addition to direct healthcare financial savings, implementation of CYP2C19 genotyping in IS/TIA has potential value to the NHS of approximately £91M and £454M over one and five years respectively1.\n \nDr Gino Miele, CEO of genedrive plc, said: \"With recent NICE guid...